Abacavir

This classification denotes a reverse transcriptase inhibitor with the molecular formula C14H18N6O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WR2TIP26VS, chemically known as 2-cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)-, (1s-cis)- but generally known as abacavir, which bears US NIH Compound Identifier 65140. Abacavir most often appears in forms succinate and sulfate, and is sometimes combined with lamivudine and zidovudine. European Medicines Agency schedules Abacavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07356MIG. The term ABACAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 11, No. 3 1997, List 38). World Health Organization schedules abacavir in its Anatomical Therapeutic Chemical (ATC) Classification. ABACAVIR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule abacavir under HS 29335995 and SITC 51576. As of Q4 2014, ABACAVIR remains the US FDA Preferred Term for this commodity. Abacavir bears US NLM identifiers UMLS ID C0663655 and NCI Concept Code C61523. SMILES: OCC1CC(N2C3NC(NC(NC4CC4)C3NC2)N)C=C1.